Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs Quest Diagnostics Inc — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $129.17, while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while ARK Autonomous Technology & Robotics ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ARKQ | DGX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $238.50 |
52-Week Low | $95.28 | $173.49 |
Market Cap | — | $26.21B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $129.39, up 1.17% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting Cathie Wood's continued bets on disruptive tech like SpaceX and Joby Aviation. Its portfolio has shifted toward quality and momentum names, blending defense stocks for resilience.
Outlook remains positive for long-term growth in AI and robotics, but high RSI levels suggest near-term overbought risk. Key risks include tech sector volatility and reliance on speculative holdings. Analysts view it as a hold with accumulation opportunities during pullbacks.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
